Mycosis fungoides is a common cutaneousT-cell lymphoma, which is usually characterized by chronic, indolence progression, with absence of typical symptoms in early stage, metastasis to lymph nodes, bone marrow and visceral organs in later stage and ultimately progression to systemic lymphoma. It can result in secondary skin infection which is a frequent cause of death. At present, no curative therapy existed. Therapeutic purpose is to induce remission, reduce tumor burden and protect immune function of patients. A case of patient with advanced severe mycosis fungoides receivingCHOP plus interferon α-2a was reported here, with disease-free survival of 7 months and overall survival of over17.0 months, and current status as well as developments of mycosis fungoides were briefly introduced.